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Abstract
Background: A recent crystal structure of monastrol in a ternary complex with the kinesin Eg5
motor domain highlights a novel, induced-fit drug binding site at atomic resolution. Mutational
obliteration of the monastrol binding site results in a monastrol-resistant, but otherwise
catalytically active Eg5 motor domain. However, considering the conformational changes at this
site, it is unclear what specific interactions stabilize the interaction between monastrol and the Eg5
motor domain.
Results: To study the molecular complementarity of the monastrol-Eg5 interaction, we used a
combination of synthetic chemistry and targeted mutations in Eg5 to measure the contribution of
specific contacts to inhibition of Eg5 in vitro and in cultured cells. Structure-activity data on
chemical derivatives, sequence analysis of Eg5 homologs from different species, and the effect of
mutations near the drug binding site were consistent with the crystal structure.
Conclusion: The mechanism of monastrol revealed by our data rationalizes its specificity for Eg5
over other kinesins and highlights a potential mechanism of drug resistance for anti-cancer therapy
targeting this site in Eg5.
Background
Kinesins are a diverse family of microtubule-based motor
proteins important for intracellular transport and cell
division in all eukaryotes [1,2]. Genetic and biochemical
dissection of kinesin function implicates specific kinesins
in the trafficking of organelles [3], signaling complexes
[4], and vesicular cargo [5]. During mitosis and cytokine-
sis, kinesins are essential for microtubule dynamics regu-
lation, assembly and maintenance of bipolar spindles,
and accurate chromosome segregation [6]. Assessing the
precise contributions of kinesins to highly dynamic proc-
esses during both interphase and mitosis is challenging.
Genetic tools such as siRNA are general and specific, but
lack temporal resolution and reversibility necessary for
detailed analysis of dynamic processes. Reversible, small
molecule inhibitors of both microtubule- and actin-based
motors are proving to be invaluable tools with which to
study their functions during cell division [7,8]. Monastrol,
a specific inhibitor of the BimC class kinesin Eg5 (also
called kinesin-5 or kinesin spindle protein, KSP) [7], has
permitted more critical analyses of Eg5 function during
spindle assembly [9,10] and as a reversible agent to syn-
chronize cells in metaphase [8]. Furthermore, inhibitors
of Eg5 and other mitotic kinesins are plausible anti-cancer
drugs now under development and testing [11,12]. They
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Ternary complex of Eg5 motor domain with monastrol and ADP-Magnesium Figure 1
Ternary complex of Eg5 motor domain with monastrol and ADP-Magnesium. Ternary complex of Eg5 motor 
domain with monastrol and ADP-Magnesium. (A) Ribbon diagram of the Eg5 motor domain (pale blue) with the nucleotide 
binding site facing down, containing ADP-Magnesium (adapted from PDB: 1Q0B). Monastrol is bound 12 Å from the nucleotide 
binding pocket, in a pocket formed by residues in α2 (green, labeled 'a2'), α3 (yellow, labeled 'a3') and loop 5 (red), a structural 
feature interrupting α2. (B) Stereoscopic view of monastrol binding site to illustrate the hydrophobic dihydropyrimidine bind-
ing surface between α2 and α3 formed primarily by the side chains of amino acid residues E116, I136, P137, Y211, L214, and 
A218. The van der Waals contact surface of Eg5 is labeled with its corresponding amino acid residue and is colored gray for 
carbon, red for oxygen, and blue for nitrogen. (C) The hydroxyphenyl ring is oriented perpendicular to the plane of the dihy-
dropyrimidine ring in a hydrophobic pocket bounded by the side chains of amino acid residues R119, W127, A133, and Y211. 
Two potential hydrogen bonding interactions between monastrol and the backbone carbonyls oxygens of amino acid residues 
E116 and E118 are highlighted in red. Distances from monastrol N to E116 and O to E118 are 2.82 Å and 2.73 Å, respectively.BMC Chemical Biology 2006, 6:2 http://www.biomedcentral.com/1472-6769/6/2
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work by disrupting the mitotic spindle, arresting cancer
cells in mitosis, and thus triggering apoptosis [13].
BimC class kinesins are widely required for bipolar spin-
dle assembly during mitosis and meiosis. They are
homotetrameric, plus-end directed kinesins that associate
with the spindle during mitosis [14-16] and their inhibi-
tion or removal generally results in spindle collapse
[7,17,18]. Spindles are dynamic, bipolar arrays of micro-
tubules that are maintained in part by a balance of forces
between oppositely directed motor proteins [19,20], and
it is likely that Eg5 provides the forces that drives the two
spindle poles apart from each other. Monastrol reversibly
inhibits microtubule gliding by Eg5 and causes spindle
collapse in cells [7]. Eg5 supports anti-parallel sliding of
microtubules in vitro [21] and during poleward flux in
Xenopus extract spindles, a process completely inhibited
by monastrol [22]. Biochemical analysis of microtubule
binding [23] and gliding by Eg5 in vitro [24] indicates
monastrol induces microtubule release and therefore
complete loss of Eg5 function as a microtubule cross-
linker and motor.
The co-crystal structure of Eg5 bound to monastrol reveals
the drug binding site in atomic detail. Monastrol binds in
a hydrophobic, induced-fit pocket between two non-con-
served features of kinesin motor domains, loop 5 and
alpha-helix 3 (α3) (Figure 1A). Upon drug binding, α3
moves 1Å relative to alpha-helix 2 (α2) and loop 5 folds
onto the drug binding site [25]. Specific hydrophobic
(Figures 1B and 1C) and polar (Figure 1C) interactions
appear in the crystal structure, but it is unclear how they
contribute to drug binding. There is direct [12] or bio-
chemical evidence that at least two other structural classes
of Eg5 inhibitors target this site, reducing dynamics of α3
and loop 5 [26]. Considering the changes in the structure
of this site, it is unclear how these interactions contribute
to drug binding, specificity, and inhibition of Eg5.
Guided by the atomic structure of the Eg5-ADP-monastrol
ternary complex, we used a combination of synthetic
chemistry, targeted mutagenesis, and protein biochemis-
try to characterize the interaction between the Eg5 motor
domain and monastrol at the atomic level. Initially, we
confirm that the structure is consistent with species-specif-
icity of monastrol in cells. A structure-activity relationship
for monastrol and mutation of target binding residues
tests the importance of individual amino acid residues
and chemical substituents to the protein-drug interaction.
Results
Confirmation of crystal structure
We crystallized the monastrol-ADP-Eg5 motor complex,
and solved its structure, independent of the published
work [25] to 1.8 Å resolution. Our structure confirms the
conformational changes in the Eg5 motor domain
induced by monastrol binding in protein crystals
obtained using distinct precipitant conditions. The details
Structure-activity relationship of monastrol derivatives Figure 2
Structure-activity relationship of monastrol deriva-
tives. (A) Scheme depicting the Biginelli condensation, a one-
pot reaction for preparing monastrol derivatives [40]. (B) 
Monastrol (circles), but not derivative 2 (squares), inhibits 
ATP hydrolysis by 500 nM hEg5-367H in KC25 buffer supple-
mented with 1 mM ATP-KOH (pH 7.0). The IC50 for monas-
trol is 5.2 +/- 0.4 µM. Each data point is the average of three 
independent experiments. (C) Summary of SAR results for 
monastrol derivatives inhibiting the catalytic activity of the 
Eg5 motor domain and inducing monoaster formation in tis-
sue culture cells, as described [28]. IC50 for each inhibitor 
was measured as described in part B. In cell-based assays, the 
potency of each derivative was obtained by treating BS-C-1 
cells as described in the methods section, and manually 
counting mitotic cells to yield a score as follows: the drug 
concentration with roughly equal monastral and bipolar spin-
dles, of < 50 µM (+++), weak compounds 50 to 200 µM (+ 
or ++), and inactive (-) compounds displayed no effect at 200 
µM. Each cell-based assay was performed in duplicate.BMC Chemical Biology 2006, 6:2 http://www.biomedcentral.com/1472-6769/6/2
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of crystallization and atomic structure determination are
available as supplemental information (see Additional
files 1 and 2).
Structure-activity relationship of monastrol derivatives in 
vitro and in cultured cells
We synthesized a variety of monastrol derivatives using
the Biginelli cyclo-condensation (Figure 2A) to determine
the small-molecule structure-activity relationship (SAR)
for inhibition of purified, recombinant Eg5 motor
domain in vitro and monoaster formation in tissue culture
cells. Overall, SARs for in vitro and  in vivo activity are
tightly correlated, and consistent with the crystal structure
of the monastrol binding site. We found that any modifi-
cation of R4 abolishes monastrol activity, supporting its
role as a hydrogen bond donor. Substituting oxygen for
sulfur at position 2 also abolishes activity (Figure 2B), pre-
sumably due to loss of favorable hydrophobic packing
interactions with Eg5. Introducing a bulky isopropyl
group at R6 abolishes activity by physically clashing with
the side chains of A218 and E215. By contrast, methyla-
tion of position 1 and a range of substitutions at position
5 do not abolish drug activity (Figure 2C). This observa-
tion strongly supports a view that the binding mode
observed by X-ray crystallography is relevant to biochem-
ical inhibition, and also the view than monopolar spindle
assembly in cells is due to Eg5 inhibition.
Monastrol is specific for vertebrate Eg5 homologs
Monastrol binds a hydrophobic pocket between loop 5
and α3 that is poorly conserved among kinesins, resulting
in specificity for vertebrate Eg5 homologs. The amino acid
side chains that contact monastrol are conserved in
human Eg5 and its homologs from X. laevis and D. rerio,
but not D. melanogaster Klp-61F,  A. nidulans BimC or
human conventional kinesin (Figure 3A). Monastrol is
known to inhibit human and Xenopus Eg5 [7,9], but not
BimC [27]. To test its effect on D. rerio Eg5 and Klp-61F,
we treated AB9 and KC167  cells with monastrol. We
observed mitotic arrest in D. rerio, and normal, bipolar
spindles in Drosophila cells (data not shown). Since Klp-
61F is required for spindle bipolarity [6], we interpret this
result to mean that Klp-61F is unaffected by monastrol. To
obtain unambiguous evidence, we cloned the motor
domain of Klp-61F and subjected the recombinant pro-
tein to ATPase assays in the presence or absence of micro-
tubules. As shown in Figure 3B, microtubule-stimulated
ATP hydrolysis by the Klp-61F motor domain is weakly
inhibited by monastrol (Figure 3B), consistent with the
monastrol-insensitivity of KC167 cells. Thus, species cross-
reactivity of monastrol is consistent with the drug binding
site observed in the crystal structure. Monastrol, or any
other drugs that bind at the same site, will probably be
inactive in invertebrate cells, and should be used as
research tools in such cells only with the greatest of cau-
tion. That said, it might be interesting to introduce drug
sensitive vertebrate Eg5 into invertebrate cells for study.
Mutational analysis of monastrol binding site
To further test the sequence requirements for monastrol
binding and specificity, we introduced mutations into the
motor domain of human Eg5. The mutations replaced
amino acid residues lining the monastrol-binding pocket
with the corresponding residues from human conven-
tional kinesin (Figure 4A), or were engineered to test if
hydrophobic interactions are required for drug binding.
Steady-state microtubule-stimulated ATP hydrolysis by
the purified recombinant motor domain provided a con-
venient measure of Eg5 activity and inhibition by monas-
trol [28]. The value for kcat  is higher than in some
publications [23,25], consistent with different buffer con-
centration, which we have previously observed have a
Sequence requirements for monastrol binding to Eg5 Figure 3
Sequence requirements for monastrol binding to 
Eg5. (A) Amino acid sequence alignment of residues near the 
monastrol binding site in Eg5 homologs from Homo sapiens, 
Xenopus laevis, Danio rerio, Drosophila melanogaster, Aspergillus 
nidulans and the corresponding residues in human conven-
tional kinesin (Kif 5B). Residues that are conserved among 
monastrol-sensitive species [7, 27, 28] are highlighted in yel-
low in all homologs where they are identical. Amino acid side 
chains expected to occlude the drug binding site are high-
lighted in red. (B) Measuring ATP hydrolysis by 400 nM hEg5-
367H (circles) or 620 nM Klp61F-364H (squares) in the pres-
ence of 1 mM ATP over a range of (S)-monastrol concentra-
tions. Each data point is the average of three independent 
experiments. The IC50 for (S)-monastrol for Eg5 and Klp-61F 
are 6.1 +/- 0.7 and 230 +/- 4 µM, respectively.BMC Chemical Biology 2006, 6:2 http://www.biomedcentral.com/1472-6769/6/2
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large effect not only on K0.5MT [27], but also kcat (unpub-
lished data). We infer that the Eg5 motor domain is
remarkably tolerant of mutations at the monastrol bind-
ing site, as all mutant protein constructs displayed nearly
wild-type catalytic activity. A few mutations had a marked
effect on the enzymatic parameters of Eg5. In particular,
mutating R119 elevated KmATP and L214I, a remarkably
conserved mutation, lowered K0.5MT. A chimera mutation
replacing loop 5 of Eg5 with that of conventional kinesin
was monastrol-resistant (Figure 4B), consistent with a
related study [26].
All of the point-mutants, with the exception of Y211M,
decreased the drug sensitivity of Eg5. Y211M actually
increased the monastrol sensitivity of Eg5, perhaps
because flexibility of the methionine side chain accom-
modates a more favorable hydrophobic interaction with
the drug. Hydrophobic packing between the thiourea and
L214 appears to be crucial for drug binding, illustrated by
the dramatic effect of even a subtle L214I mutation on
IC50. L214T mutant was resistant to monastrol, as would
be expected, but also to derivative 2 (data not shown)
with a compensating hydrophilic urea. Hydrophobic con-
tacts from R119 are required for monastrol binding, but
electrostatic interactions also appear important (Figure
4B). In summary, our mutational changes near the bind-
ing site are consistent with the Eg5-monastrol structure
and provide a number of catalytically active mutants of
Eg5 that might be useful to examine spindle assembly and
drug resistance in Eg5 by expression in cells.
Discussion
Monastrol is a convenient reagent for mitosis research,
but its specificity hitherto has not been established. Exper-
iments designed to probe the role of Eg5 in the mitotic
spindle and post-mitotic neurons are predicated on the
assumption that monastrol is a specific inhibitor of Eg5
[29,30]. It is reassuring to note that no kinesin protein
contains sequences in loop 5 and α3 that are part of the
monastrol binding site. Loop 5 is highly divergent among
different kinesin classes [25], and the sequence of α3 near
the monastrol binding site is not conserved. Indeed, most
kinesins project bulky amino acid side chains into the
putative monastrol binding pocket that would preclude
drug binding (Figure 3A). Thus, monastrol should be
highly selective among kinesins. However, we note it
could easily target unexpected proteins. Its affinity is fairly
low by drug standards, and it is often used on cells at 100
µM or more. At such high concentrations, any hydropho-
bic molecule could bind multiple targets. As a cell biology
reagent, monastrol should be replaced with more potent
compounds as soon as they are available. One such rea-
gent is S-trityl cysteine, which is inexpensive, more potent
than monastrol and appears to target a similar site in Eg5
[26]. In the meantime, pharmacological SAR of different
Eg5 inhibitors is a useful approach to implicate a specific
role for Eg5 in biological processes [22].
Monastrol binds a cryptic site that would not have been
discovered by virtual screening methods previously
employed to find novel small-molecule kinesin inhibitors
[31]. It is also notable that this is a flexible drug binding
site, which is also the target for the binding of S-trityl
cysteine [27] and 3,5-diaryl-4,5-dihydropyrazoles [12],
compounds that look very dissimilar in terms of overall
shape and charge. While this allosteric site is fortuitous for
drug discovery, its evolutionary conservation among ver-
tebrates leads us to speculate that it is required for Eg5
function in vivo, either as part of the conformational cycle
of the motor domain, or more speculatively by binding an
unknown endogenous ligand that could be a protein or a
small molecule. Our preliminary small molecule SAR did
not yield more potent monastrol derivatives, but high-
lighted some of the functional groups contributing to Eg5
inhibition. For instance, the specific hydrogen-bonding
interaction between Eg5 and the phenol group of monas-
trol as well as hydrophobic packing of the thiophenol
appears crucial for drug binding (Figure 2B), similar to the
Mutagenesis of the monastrol binding site in human Eg5 Figure 4
Mutagenesis of the monastrol binding site in human 
Eg5. (A) Design of mutations in the human Eg5 motor 
domain. Amino acid side chains that are not conserved 
between Eg5 and conventional kinesin were targeted, either 
introducing chimeric or rationally designed mutations 
(asterix for targeted point mutants) to test the contribution 
of residues to the drug-sensitivity of Eg5. (B) Steady-state 
enzymatic parameters for engineered human Eg5 motor 
domain mutants. Steady-state ATP hydrolysis by Eg5 was 
measured using an NADH-enzyme coupled assay varying the 
concentration of ATP, microtubules, or monastrol to obtain 
the microtubule concentration for half-maximal stimulation 
(K0.5MT), the maximal rate of microtubule-stimulated ATP 
hydrolysis (kcat), and the concentration of monastrol that 
inhibits basal ATP hydrolysis by 50 % (IC50), as described 
[28].BMC Chemical Biology 2006, 6:2 http://www.biomedcentral.com/1472-6769/6/2
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interactions observed between dihydropyrazoles and Eg5
[12]. A report published during revision of this manu-
script described a SAR for monastrol derivatives consistent
with our results. However, some inhibitors displaying
weak activity in their assays, most notably derivative 2
(Figure 2B) and 4e, were completely inactive in our hands.
The discrepancy can be explained by the higher sensitivity
of their assay [32].
Although mutations at this site permit microtubule-stim-
ulated ATP hydrolysis by the motor domain of Eg5, their
effect on the kinetic parameters KmATP, K0.5MT, kcat, and
IC50 indicate subtle effects on its catalytic cycle. Monastrol
decreases the microtubule affinity of Eg5, and one might
expect mutations that lower K0.5MT to raise IC50  for
monastrol. This may be true for the L214I, a subtle muta-
tion that would effect transitions between ordered and
disordered states of α3 [26]. A surprising result of our
mutational analysis showed that mutating R119 greatly
elevated KmATP (Figure 4B), indicating a weakened affin-
ity for ATP. In light of a proposed model whereby monas-
trol stabilizes a pre-ATP hydrolysis conformation of the
Eg5 motor domain [23], this merits further investigation
using non-equilibrium enzyme kinetics. The mutant
L214T, which introduces a hydrophilic residue into a pre-
viously hydrophobic environment, lowers kcat, as well as
overall protein expression (data not shown), as might be
expected. Systematic mutational analysis around the
monastrol binding sight might identify mutants with dis-
crete effects on microtubule and ATP binding to help dis-
sect the catalytic cycle of kinesin motor proteins.
The monastrol binding site is a promising target for anti-
cancer drug development, but our data showing that rela-
tively subtle mutation confer resistance to drug binding
without blocking enzymatic function sound a note of cau-
tion; Eg5 has potential for sporadic mutation to result in
clinical resistance. Pressure to conserve residues at a sub-
strate binding pocket is one explanation for the selectivity
of non-competitive inhibitors among related proteins as
compared to substrate-competitive inhibitors [33]. The
clinical correlate of this biological phenomenon is that
non-competitive inhibitors, exemplified by non-nucleo-
side reverse transcriptase inhibitors (NNRTIs) to treat HIV
infection, display fewer non-specific side effects but clini-
cal resistance is easily acquired by mutations in the target
protein [34]. Monastrol is a prototype anti-mitotic agent
that displays many of the same benefits and limitations of
NNRTIs. One obvious concern, if Eg5 inhibitors devel-
oped as anti-mitotic drugs also target this site, is the rapid
appearance of resistant clones, especially in the context of
DNA damaging agents employed clinically. The impor-
tance of the monstrol binding site could be explored by
gene replacement experiment, swapping drug resistant
point mutants for the wild-type protein. Previously such
experiments have been hard in vertebrate cells, but recent
progress with SiRNA and bacterial artificial chromosome
technologies' makes them feasible, even in human cancer
cells [35].
Conclusion
The published crystal structure of monastrol in a ternary
complex with the Eg5 motor domain and ADP [25], as
well as our own structural studies arrived independently,
are consistent with the structure-activity relationship of
monastrol against purified, recombinant Eg5 motor
domain in vitro and in tissue culture cells. Consistent with
sequence homology at the drug binding site, we demon-
strate the monastrol does not target Klp-61F, the Eg5
homolog in D. melanogaster, but arrests D. rerio cells in
mitosis. Finally, we performed mutational analysis at
drug-binding residues which high-lights flexibility at the
drug binding site, and suggests a mechanism for genetic
resistance to monastrol, and possibly more potent Eg5
inhibitors currently being developed as anti-mitotic
agents in cancer chemotherapy.
Methods
Reagents were obtained from Sigma-Aldrich, unless other-
wise indicated. Experimental stocks of taxol (10 mM),
PMSF (100 mM), benzimidine hydrochloride (200 mM),
1000 × LPC (10 mg/ml each of leupeptin, pepstatin, and
chymostatin), and monastrol derivatives (200 mM) were
prepared as DMSO solutions, aliquoted, and stored at -
20°C until use. KC25, the standard buffer used in bio-
chemical experiments described below consists of 20 mM
PIPES-KOH (pH 6.8), 25 mM KCl. All tissue culture
media were supplemented with heat inactivated fetal calf
serum (HyClone), penicillin and streptomycin (Cellgro,
Mediatech).
Structural analysis of Eg5-monastrol-ADP complex
We determined the atomic structure of the Eg5-ADP-
monastrol complex using multi-wavelength anomalous
dispersion to a resolution of 1.80 Å. Although our protein
crystals grew under different precipitant conditions than
those described by Yan and colleagues, the atomic struc-
ture of the Eg5 motor domain were essentially identical to
the published results [25]. The atomic coordinates are
deposited in the protein database as 1X88. The details of
our crystallographic refinement are available as support-
ing information. Figures in this report were prepared
using PyMol [36] based on the structure reported by Yan,
et. al. [25], (PDB: 1Q0B).
Tissue culture assays
Conditions for growing the following cell lines are as
described: D. rerio AB9 (37), D. melanogaster KC167 [38],
and BS-C-1 green monkey kidney cells [7]. For immun-
ofluorescence microscopy, cells were grown on 12 mmBMC Chemical Biology 2006, 6:2 http://www.biomedcentral.com/1472-6769/6/2
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circular coverslips to 30 % confluence, treated medium
supplemented with drug and 0.2% DMSO, or a DMSO
alone, for 6 hours, fixed with formaldehyde, and stained
for DNA and microtubules, as described [28]. D. mela-
nogaster  KC167 cells were cultured in Schneider's Dro-
sophila Medium (GIBCO) whereas D. rerio AB9 cells and
BS-C-1 green monkey kidney cells were cultured at 37°C
in Dulbecco's Minimal medium in the presence of 10 %
heat inactivated fetal calf serum.
Cloning, purification, and characterization of Klp-61F 
motor domain
The motor domain from D. melanogaster Klp-61F (amino
acid residues 1 to 364) with an engineered C-terminal
His6 affinity tag was sub-cloned by PCR from a cDNA
library (gift of Christine Field) into pRSETa as described
[28]. The sequence agreed with the published sequence
for the Klp-61F (NP_476818.1 GI:17136642). Expression
and purification of the Klp-61F motor domain was per-
formed, as described [28].
Synthesis of monastrol derivatives
Monastrol derivatives were synthesized via the Biginelli
condensation, purified by silica-gel chromatography, and
characterized by 1H-NMR and tandem liquid chromatog-
raphy/electrospray ionization mass spectrometry, as
described [28]. The 1H-NMR resonances in d6-DMSO for
each derivative, unless previously reported, are listed
below:
Derivative 1: [ethyl 6-methyl-4-(3-hydroxyphenyl)-2-thi-
oxo-1-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxy-
late] : 9.79 (s, 1H), 9.44 (s, 1H), 7.11 (t, J = 8.5 Hz, 1H),
6.6 (m, 3H), 5.13 (d, J = 4 Hz, 1H), 4.11 (q, J = 7.5 Hz,
2H), 3.48 (s, 3H), 2.50 (s, 3H), 1.18 (t, J = 7.5 Hz, 3H).
Derivative 2: [ethyl 6-methyl-4-(3-hydroxyphenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxylate] : 9.35 (s,
1H), 9.14 (s, 1H), 7.67 (s, 1H), 7.09 (t, J = 8 Hz, 1H), 6.67
(d, J = 7 Hz, 1H), 6.66 (s, 1H), 6.62 (d, J = 7.5 Hz, 1H),
5.06 (d, J = 3 Hz, 1H), 4.00 (q, J = 6.5 Hz, 2H), 2.23 (s,
3H), 1.13 (t, J = 7.5 Hz, 3H).
Derivative 4a: [ethyl 6-methyl-4-phenyl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate] : 10.33 (s, 1H), 9.64
(s, 1H), 7.35 (t, J = 7.5 Hz, 2H), 7.28 (t, J = 7 Hz, 1H), 7.22
(d, J = 7 Hz, 2H), 5.17 (d, J = 3.5 Hz, 1H), 4.01 (q, J - 7
Hz, 2H), 2.29 (s, 3H), 1.11 (t, J = 7 Hz, 3H).
Derivative 4c: [ethyl 6-methyl-4-(3-fluorophenyl)-2-thi-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate] : 10.41
(s, 1H), 9.69 (s, 1H), 7.41 (dd, J = 8.5, 5.5 Hz, 1H), 7.14
(dd, J= 2, 6.5, 1H), 7.07 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 10
Hz, 1H), 5.20 (d, J = 3.5 Hz, 1H), 4.31 (q, J = 7 Hz, 2H),
2.30 (s, 3H), 1.11 (t, J = 7.5 Hz, 3H).
Derivative 4d: [ethyl 6-methyl-4-(3-methoxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate] :
10.33 (s, 1H), 9.63 (s, 1H), 7.27 (t, J = 8 Hz, 1H), 6.85 (d,
J = 7 Hz, 1H), 6.78 (d, J = 7.5 Hz, 1H), 6.76 (s, 1H), 5.15
(d, J = 4 Hz, 1H), 4.03 (q, J = 7.5 Hz, 2H), 3.73 (s, 3H),
2.28 (s, 3H), 1.12 (t, J = 7.5 Hz, 3H).
Derivative 4e: [ethyl 6-methyl-4-(3-bromophenyl)-2-thi-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate] : 10.41
(s, 1H), 9.68 (s, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.38 (s, 1H),
7.34 (t, J = 7.5 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 5.17 (d,
J = 3.5 Hz, 1H), 4.03 (q, J = 7.5 Hz, 2H), 2.30 (s, 3H), 1.13
(t, J = 7 Hz, 3H).
Derivative 5a: [methyl 6-methyl-4-(3-hydroxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-ketone]: 10.23 (s,
1H), 9.69 (s, 1H), 9.43 (s, 1H), 7.11 (t, J = 7.5 Hz, 1H),
6.6 (m, 3H), 5.19 (d, J = 3.5 Hz, 1H), 2.31 (s, 3H), 2.16
(s, 3H).
Derivative 5b: [isobutyl 6-methyl-4-(3-hydroxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate]:
10.30 (s, 1H), 9.60 (s, 1H), 9.42 (s, 1H), 7.12 (t, J = 8Hz,
1H), 6.65 (m, 3H), 5.09 (d, J = 4 Hz, 1H), 3.81 (d, J = 7
Hz, 2H), 2.31 (s, 3H), 1.78 (m, J = 7 Hz, 1H), 0.77 (d, J =
6.5 Hz, 6H).
Derivative 5c: [benzyl 6-methyl-4-(3-hydroxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate]:
10.34 (s, 1H), 9.62 (s, 1H), 9.44 (s, 1H), 7.29 (d, J = 5.5,
2H), 7.16 (m, 3H), 7.11 (t, J = 8 Hz, 1H), 6.65 (m, 3H),
5.12 (d, J = 4 Hz, 1H), 5.07 (q, J = 12 Hz, 2H), 2.31 (s,
3H).
Derivative 6: [ethyl 6-isopropyl-4-(3-hydroxyphenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate] :
9.74 (s, 1H), 9.59 (s, 1H), 9.45 (s, 1H), 7.13 (t, J = 7.5 Hz,
1H), 6.65 (m, 3H), 5.08 (d, J = 3.5 Hz, 1H), 4.10 (7t, J =
7 Hz, 1H), 4.01 (q, J = 6.5 Hz, 2H), 1.17 (dd, J = 25, 6.5
Hz, 6H), 1.10 (t, J = 6.5 Hz, 3H).
Preparation of Eg5 motor domain mutants
We used a modified PCR mutagenesis protocol [39] to
introduce mutations into hEg5-367H, a plasmid encoding
the C-terminally His6-tagged motor domain (amino acid
residues 1–367) of human Eg5. The wild-type and mutant
proteins were expressed and purified using Ni-NTA affin-
ity chromatography and concentrated to between 3 and
10 mg/ml protein as described [28].
Measurement of ATP hydrolysis kinetics
ATP hydrolysis by recombinantly expressed kinesin motor
domains was measured using an NADH-enzyme coupled
assay [28]. ATP hydrolysis was measured in KC25 buffer
supplemented with 5 µM taxol, 1 mM ATP-KOH (pH 7.0),BMC Chemical Biology 2006, 6:2 http://www.biomedcentral.com/1472-6769/6/2
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the appropriate concentration of motor domain, and the
appropriate concentrations of taxol-polymerized microtu-
bules. ATP hydrolysis as a function of microtubule con-
centration was fit to the Michaelis-Menten equation to
determine the maximal rate of microtubule-stimulated
ATP hydrolysis (kcat) and the microtubule concentration
for half-maximal stimulation (K0.5MT) according to the
equation: V = kcat × ([MT]/([MT] + K0.5MT). A similar anal-
ysis, V = V1 µM × ([ATP]/([ATP] + KmATP), was used to
measure KmATP. Here, V1 µM was the maximal rate of ATP
hydrolysis by hEg5-367H or its mutants at 1 µM microtu-
bule concentration. To measure the potency (IC50) of
monastrol derivates, we measured ATP hydrolysis in the
presence of 1 µM taxol-stabilized microtubules at various
drug concentrations and fit the data to the function: V = 1-
Vmax ([drug]/([drug] + IC50).
Abbreviations
ATP: Adenosine 5'- triphosphate
ADP: Adenosine 5'-diphosphate
DMSO: Dimethyl sulfoxide
LPC: Mixture of leupeptin, pepstatin, and chymostatin
MT: Microtubule
NADH: Beta-Nicotinamide adenine dinucleotide,
reduced
NNRTI: Non-nucleotide reverse transcriptase inhibitor
PDB: Protein database
PIPES: Piperazine-1,4-bis(2-ethanesulfonic acid)
PMSF: Phenyl methyl sulfonyl fluoride
SAR: Structure activity relationship
SiRNA: Small inhibitory Ribonucleic Acid
TCEP: Tris (2-carboxyethyl) phosphine
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